Inclusion Criteria:

- Participant must be scheduled to undergo standard of care prostatectomy for presumed
localized prostate cancer at the NIH Clinical Center.

- Have had or will undergo multiparametric endorectal coil 3T MR at the NIH clinical
center

- Recent (within 12 months of study entry) trans-rectal biopsy indicating the presence
of adenocarcinoma of the prostate gland

- Participant must be 18 years or older.

- ECOG Performance grade of 0 to 2. (see Appendix 1)

- Ability to understand and provide informed consent. All subjects must sign a
document of informed consent indicating their understanding of the investigational
nature and risks of the study before any protocol related studies are performed.

- Participants of childbearing potential must agree to use an acceptable form of birth
control, defined as abstinence, barrier or other acceptable, effective contraceptive
method until 7 days after the infusion of study drug.

Exclusion Criteria:

- Participants for whom participating would significantly delay the scheduled standard
of care therapy.

- Subjects must not have prostate biopsies performed within 12 weeks before imaging; or
within 8 weeks before imaging providing that the absence of hemorrhage is confirmed
by MR imaging.

- SGOT and SGPT ≥ 2 x of the upper limits of normal; total bilirubin, of ≥ 1.5 x the
upper limits of normal or ≥ 3.0 mg/dl in patients with Gilbert's syndrome.

- Administered a radioisotope within 5 physical half lives prior to study enrollment.

- Patients with severe claustrophobia unresponsive to oral anxiolytics

- Subjects weighing ≥350 lbs or are unable to fit within the imaging gantry

- Subjects who have received androgen deprivation therapy.

- Subjects with any medical condition or other circumstances that, in the opinion of
the Investigator, would significantly decrease obtaining reliable data, achieving
study objectives or completing the study.